文献速递白血病

PRMT1介导的FLT3精氨酸甲基化促进FLT3-ITD阳性急性髓系白血病维持

PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia.
PubMed 文献 · Blood · 2019-06-19

该研究探讨PRMT1介导的FLT3精氨酸甲基化在FLT3-ITD阳性AML维持中的作用。研究发现PRMT1在AML细胞中表达显著增高,催化FLT3-ITD蛋白R972/973位点甲基化,且该甲基化不依赖激酶活性。在PDX和小鼠AML模型中,AC220联合I型PRMT抑制剂MS023较单用AC220增强清除FLT3-ITD阳性AML细胞。

要点

  • PRMT1在AML细胞中表达较正常造血细胞显著增高,优先与FLT3-ITD协同促进AML维持。
  • PRMT1催化FLT3-ITD蛋白R972/973位点甲基化,以FLT3甲基化依赖方式促进白血病细胞生长。
  • 在PDX和小鼠AML模型中,AC220联合MS023较单用AC220增强清除FLT3-ITD阳性AML细胞。

核心结论

  • PRMT1介导的FLT3甲基化促进AML维持,提示联合PRMT1抑制与FLT3 TKI治疗可能是清除FLT3-ITD阳性AML细胞的有前景策略。

研究设计与样本

  • 研究采用全基因组分析、免疫共沉淀实验和PRMT1敲除小鼠研究,并在患者来源异种移植(PDX)和小鼠AML模型中验证。

主要发现

  • AML细胞中PRMT1表达较正常造血细胞显著增高。
  • PRMT1优先与FLT3-ITD协同,遗传或药理抑制PRMT1显著阻断FLT3-ITD阳性AML细胞维持。
  • PRMT1催化FLT3-ITD蛋白R972/973位点甲基化,并以FLT3甲基化依赖方式促进白血病细胞生长。
  • FLT3-ITD甲基化在激酶抑制后仍持续存在于FLT3-ITD阳性AML细胞中,表明甲基化独立于激酶活性发生。
  • 在PDX和小鼠AML模型中,AC220联合I型PRMT抑制剂MS023较单用AC220增强清除FLT3-ITD阳性AML细胞。

临床怎么用

  • 对于FLT3-ITD阳性AML,PRMT1介导的FLT3甲基化在激酶抑制后持续存在,联合PRMT1抑制与FLT3 TKI可能增强清除FLT3-ITD阳性AML细胞。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The presence of FMS-like receptor tyrosine kinase-3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukemia (AML) is associated with poor clinical outcome. FLT3 tyrosine kinase inhibitors (TKIs), although effective in kinase ablation, do not eliminate primitive FLT3-ITD+ leukemia cells, which are potential sources of relapse. Thus, understanding the mechanisms underlying FLT3-ITD+ AML cell persistence is essential to devise future AML therapies. Here, we show that expression of protein arginine methyltransferase 1 (PRMT1), the primary type I arginine methyltransferase, is increased significantly in AML cells relative to normal hematopoietic cells. Genome-wide analysis, coimmunoprecipitation assay, and PRMT1-knockout mouse studies indicate that PRMT1 preferentially cooperates with FLT3-ITD, contributing to AML maintenance. Genetic or pharmacological inhibition of PRMT1 markedly blocked FLT3-ITD+ AML cell maintenance. Mechanistically, PRMT1 catalyzed FLT3-ITD protein methylation at arginine 972/973, and PRMT1 promoted leukemia cell growth in an FLT3 methylation-dependent manner. Moreover, the effects of FLT3-ITD methylation in AML cells were partially due to cross talk with FLT3-ITD phosphorylation at tyrosine 969. Importantly, FLT3 methylation persisted in FLT3-ITD+ AML cells following kinase inhibition, indicating that methylation occurs independently of kinase activity. Finally, in patient-derived xenograft and murine AML models, combined administration of AC220 with a type I PRMT inhibitor (MS023) enhanced elimination of FLT3-ITD+ AML cells relative to AC220 treatment alone. Our study demonstrates that PRMT1-mediated FLT3 methylation promotes AML maintenance and suggests that combining PRMT1 inhibition with FLT3 TKI treatment could be a promising approach to eliminate FLT3-ITD+ AML cells.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. He X, Zhu Y, Lin YC, et al. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2019. PMID: 31217189. doi:10.1182/blood.2019001282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。